regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from managed care entities. Such insurers are often creating barriers to access, including high price criteria and prior authorization that restrict user availability. Industry